gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin rnai hotmdco givlaari deal
highlight week novemb novemb medicin compani buy chardan top pick
share rose novemb bloomberg media sourc report mdco attract
take-over interest novarti unrat novemb novarti announc enter agreement
acquir medicin compani premium novemb mdco close price valu
compani bn fulli dilut equiti basi news mean chardan long-held mdco thesi play
price repres perform mdco sinc
januari inclus pt chardan top pick portfolio
buy announc fda approv rnai therapeut givlaari givosiran acut hepat porphyria ahp ahead
februari pdufa date annual net price expect alnylam also announc
new framework value-bas agreement payor limit financi exposur payor number
ahp patient higher estim buy announc collabor novo
nordisk unrat discoveri develop rnai therapeut liver-rel cardio-metabol diseas
collabor util dicerna galxc platform explor liver cell target indic may
chronic liver diseas non-alcohol steatohepat nash type diabet obes rare diseas dicerna
receiv up-front cash payment mm mm equiti invest premium dicerna also entitl
mm annual first year mm per target mileston payment plu tier royalti sale
deal follow unrat alnylam deal nash announc march
buy partner unrat announc initi safeti efficaci data
patient treat ex vivo crispr therapi data cover patient transfusion-depend beta
thalassemia tdt sever sickl cell diseas scd treat on-going phase i/ii studi
patient experienc sae none deem relat patient exceed
clinic efficaci metric respect studi tdt patient remain transfus independ month post-
dose scd patient reach fetal hemoglobin hbf level vaso-occlus crise month
unrat announc submit market author applic
base gene therapi gt valoctocogen roxaparvovec valrox hemophilia hema ema recent grant
biomarin request acceler assess thu reduc review time day day
look forward novemb novemb novemb societi neuro-oncolog sno
annual meet continu phoenix program includ tocagen neutral vbl buy
unrat novemb et novarti host investor call acquisit
medicin compani novemb buy report result fiscal year
end septemb estimate novemb uniqur buy chardan top pick
present network european transplant restor nectar annual meet cardiff uk
weekli price move vivo genet medicin aav srna mrna vivo gene edit
note mdco week track gm portfolio due lack rnai platform
upcom chardan genet medicin event contact chardan rsvp
research team led dr georg church harvard medic school publish pna novemb print
novemb paper detail gt approach treat age-rel diseas note age
pleas refer import disclosur inform regul analyst certif found page report
import risk factor host chronic diseas team design test sever aav cocktail
would confront multipl age-rel diseas team identifi cocktail compris
effect treat differ age-rel diseas name obes type ii diabet heart failur renal failur
test base longevity-associ gene fibroblast growth factor klotho
transform growth link metabol glucos handl klotho known
regul intracellular calcium thu protect role heart kidney patholog
shown play role hypertroph cardiomyopathi immun recruit extracellular matrix format
team use vector chosen high liver transduct effici develop overexpress
klotho solubl form mous transform growth factor- receptor repress
team verifi express level saw increas decreas circul
increas circul klotho mice inject team show combin
mitig obes phenotyp high-fat diet hfd age-rel obes model
gt combin contain rescu type ii diabet phenotyp alon combin
protect effect renal failur model combin either aav-
klotho largest effect heart failur model togeth result indic combin
may potenti effect treat age-rel diseas
new gt approach church colleagu may provid signific advantag and/or synergist
current standard-of-car often requir use multipl individu small molecul treatment often
off-target effect thu result patient experienc larg number side effect gene therapi approach
develop serv treatment prevent minim off-target effect albeit gt-relat
side effect determin address multipl age-rel diseas time result could transform
global societi mention like cost-effect given abil address multipl diseas note
signific approach anoth exampl aav gt field move beyond monogen diseas theme
highlight februari review research earli select exampl compani develop
address polygen age-rel diseas includ adverum biotechnolog neutral askbio privat axov
gene therapi buy biotech privat meiragtx buy chardan top pick buy
chardan top pick tenaya therapeut privat neutral
crsp buy bet optim condit crsp novemb livshit
crispr partner announc collabor unrat
focus develop novel condit regimen hematopoiet stem cell therapi transplant
us move signal vertex commit collabor crispr tx gene editing-bas
therapi current phase i/ii studi treat scd tdt
mount interest novel less toxic condit regimen hsc-base therapi matur evidenc
unrat bluebird bio analog collabor forti seven unrat announc novemb
newly-announc collabor focu engin toxin bodi etb platform select
deplet target cell conduct research target select vertex
crsp buy earli data herald era crispr-bas tx novemb livshit
crispr togeth partner announc initi safeti efficaci data
patient treat ex vivo crispr therapi thu far us promis start ex vivo program
data cover patient tdt scd treat on-going phase i/ii studi
patient experienc number sae respect none deem relat
rather sae line report busulfan condit underscor
move vertex toward develop novel condit regimen
overal thu far earli efficaci signal term fetal hemoglobin induct clinic metric look
posit us line report bluebird bio unrat lentiglobin
mdco buy thesi final final play novemb amusa
medicin compani chardan top pick share novemb bloomberg
media sourc report mdco attract take-over interest novarti report us
credibl consist publish view name recent messag septemb research
emphas long-held thesi mdco believ compani acquir year ahead
view mdco target and/or earlier statement mdco
see upsid activist interest break-up sale
page
anoth seri good year perform chardan top pick chardan top
pick novemb averag return sinc inclus portfolio
alnylam announc earli surpris fda approv compani rnai therapeut givosiran
treatment acut hepat porphyria ahp brand name product givlaari approv come
month establish pdufa date februari givosiran review fda
prioriti review previous grant breakthrough therapi orphan drug design
us givosiran also current review acceler assess ema treatment patient
ahp receiv prioriti medicin prime design orphan drug design ema
approv expect addit approv japan countri could obtain
compani intend primari respons commerci givlaari
collabor agreement unrat leverag relationship ironwood
sale forc promot drug gastroenterologist
similar way onpattro launch compani util value-bas price agreement
commerci govern payor expect annual net price givlaari estim
genet medicin news novemb novemb
buy announc collab nvo unrat rnai tx cardio-metabol diseas novemb
dicerna announc collabor novo nordisk unrat discoveri develop rnai
therapeut liver-rel cardio-metabol diseas collabor util dicerna galxc platform
explor liver cell target indic may includ sub-seg chronic liver diseas non-alcohol
steatohepat nash type diabet obes rare diseas
agreement dicerna conduct discoveri preclin develop novo nordisk
respons develop dicerna receiv up-front payment mm cash mm equiti
invest premium dicerna also entitl mm annual first year mm
per target mileston payment plu tier royalti sale
collabor dicerna rnai collabor big cap pharma compani announc past month
dicerna collabor roch unrat announc octob focu
rnai therapeut chronic hepat viru hbv infect collect collabor infus
dicerna mm up-front cash mm equiti invest
buy receiv fda odd gt gangliosidosi novemb
xon unrat report data pi trial plasmid-bas gt heart failur novemb
ortx unrat announc ema acceler assess ex vivo lenti gt mld novemb
phio unrat price mm public offer common stock novemb
unrat appoint dr morgan sheng board director novemb
carib bioscienc privat publish type crispr-ca system genom edit novemb
mdco buy present result piii trial rnai tx inclisiran hefh novemb
medicin compani present american heart associ aha scientif session result
phase studi sirna therapeut inclisiran heterozyg famili hypercholesterolemia hefh
trial met primari secondari endpoint compani plan submit data medic journal
data show placebo-adjust ldl-clower mg/dl time-averag placebo-adjust
reduct mg/dl day numer lower seriou treatment-emerg advers
event vs treatment-rel liver renal abnorm increas number inject
compani plan file nda us eu recal previous
highlight investor focu ascvd indic inclisiran evalu
pivot trial also hefh given million-pati us hefh market
buy present pi data rnai therapeut novemb
anp asx unrat present data phase ii trial aso tx dmd novemb
excis privat present crispr-bas gene edit hsv jc viru novemb
tigem publish aav-deliv microrna approach rho-adrp lca novemb
page
cyad unrat report result provid busi updat novemb
unrat announc uk auth pi/ii trial car-treg tx kidney transplant novemb
gnpx unrat report preclin data gt oncoprex pembro lung cancer novemb
crsp buy announc price public offer common stock novemb
aruv privat announc appoint dr william chou chief execut offic novemb
 minnesota publish cell engin without double-strand break use novemb
unrat announc close agreement unrat novemb
ly fp unrat report cash posit novemb
hust publish transduct lower motor neuron serotyp novemb
unrat publish studi show prednisolon affect transgen express novemb
ntgn unrat announc corpor restructur focu cell therapi program novemb
cll unrat win patent challeng method use gene edit cell novemb
prqr buy receiv fda odd aso tx treatment adrp novemb
unrat complet enrol piii trial gt chm novemb
phio unrat announc expans collab karolinska institutet sdrnai tx novemb
selb unrat announc appoint carri cox chairman board director novemb
pact pharma privat announc appoint uneek mehra cfo novemb
unrat announc submiss gt valrox hema novemb
biomarin announc submit market author applic gene therapi
gt valoctocogen roxaparvovec valrox treatment hemophilia hema ema recent grant
biomarin request acceler assess thu reduc review time day day
note valrox potenti gt approv treatment hema
clinical-stag competitor hema gt includ unrat /pfizer unrat
neutral takeda unrat preclinical-stag competitor hema includ privat
uniqur buy chardan top pick addit player target hema via gene edit
approach includ privat toolgen buy
excis privat present gene edit hiv novemb
privat appoint dr annahita keravala svp gene therapi novemb
cyad unrat receiv mm non-dilut fund walloon region novemb
buy host day provid updat pipelin progress novemb
rhhbi unrat file extens tender offer neutral novemb
neutral present piii data cancer-select gt fc rhgg novemb
unrat present data adenovir gt control /- nivolumab rgbm novemb
ziopharm present societi neuro-oncolog sno annual meet interim data on-going studi
control plu veledimex ad monotherapi combin nivolumab
inhibitor recurr progress glioblastoma multiform rgbm adult
result ad monotherapi patient main phase trial well
patient phase expans trial patient receiv viral particl
deliv intra-tumor plu veledimex day drug-rel toxic compar across
trial drug-rel death grade cytokin releas syndrom occur
patient main trial patient expans trial serum seen day
follow peak downstream ifn- day virtual subject commensur increas seen
page
mediat activ peripher blood immun cell expans studi mri demonstr pseudoprogress
follow reduct size lesion nonmeasur main studi subject unifoc lesion
receiv low-dos concurr steroid reach median overal surviv mo month neg impact
high-dos steroid note mo mo yet reach subset patient
expans studi mean follow-up month
result phase trial ad combin nivolumab show median overal
surviv reach mean follow-up month drug-rel toxic compar
main studi serum detect patient administr mri show pseudoprogress
follow partial respons phase ii trial ad cemiplimab-rwlc anoth inhibitor
compani mention report
page
select catalyst genet medicin coverag
figur regenxbio rocket solid uniqur expect import data read-out
report initi phase data process fanconi anemia
provid follow-up data piib dose-confirm studi hemb
initi phase data patient leukocyt adhes deficiency-i lad-i
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
submit ind methylmalon acidemia mma
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
initi dose phase trial hemophilia
report biomark data phase i/ii ignit dmd trial
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
file ind cta pomp diseas
provid updat phase i/ii studi hemophilia
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
page
select catalyst outsid genet medicin coverag
report initi phase i/ii data transfusion-depend thalassemia
bay report initi phase i/ii data hemophilia
report long-term follow-up data wiskott-aldrich syndrom
report data phase trial r/r aml md
report initi data phase i/iia trial r/r nhl
lentiglobin report addit data trial tdt sickl cell diseas
initi pivot phase trial rdeb
suvodirsen interim data open-label extens studi dmd
initi phase ib trial beta-thalassemia
initi clinic trial charcot-marie-tooth type
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind inherit amyotroph later sclerosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
file ind gangliosidosi
dose patient optim lenti vector trial fabri diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm prevail genet therapytickerratingccm ptupsideclosechang changemc mm dicerna gene editingtickerratingccm ptupsideclosechang changemc mm intellia pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
